1Niacin vs. Nicotinamide — Critical Pharmacological Distinction
| Pharmacological Property | Nicotinic Acid (Niacin) | Nicotinamide (Niacinamide) | Extended-Release Niacin |
|---|---|---|---|
| Cutaneous Flushing | Yes (prostaglandin-mediated) | No flushing | Reduced severity |
| Lipid-Lowering Effect | Yes (HDL ↑, Triglycerides ↓) | No lipid-lowering effect | Yes |
| Pellagra Treatment | Effective | Preferred (avoids flushing) | Effective |
| Hepatotoxicity Risk | Low at standard doses | Low | Higher risk at high doses |
2Pellagra in Indian Clinical Practice
Pellagra classically presents with the 4 Ds: Dermatitis (Casal's necklace photosensitive rash), Diarrhea, Dementia, and Death. It remains encountered in sorghum/jowar-eating populations, chronic alcohol use disorder, and patients receiving long-term isoniazid therapy without adequate pyridoxine (B6) and niacin co-supplementation.
3Niacin for Dyslipidemia & Managing Flushing
Niacin (nicotinic acid) is among the most potent agents for raising HDL cholesterol and lowering triglycerides. However, because major cardiovascular outcome trials (AIM-HIGH, HPS2-THRIVE) demonstrated no incremental vascular benefit when added to background statin therapy, its primary role is reserved for severe hypertriglyceridemia or statin intolerance.
Flushing Mitigation: Niacin-induced cutaneous flushing is mediated by GPR109A activation and prostaglandin release. Co-administration of aspirin 325 mg (or ibuprofen 200 mg) 30 minutes prior to dosing, taking niacin with meals, and slow titration significantly attenuates this side effect. Tolerance typically develops within 2 to 4 weeks of consistent dosing.